Paper30967904
Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation.
Filgueira NA. World J Hepatol, 2019. Cited by 111 papers, by iCite.
Cite this record
ConductScience Library. Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation. Papers, record 30967904. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30967904
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References77
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11391528 | Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. | Hepatology | 2001 | https://conductscience.org/library/papers/11391528 | PubMed |
| 2 | 15048797 | Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. | Liver Transpl | 2004 | https://conductscience.org/library/papers/15048797 | PubMed |
| 3 | 16386569 | Does preoperative fine needle aspiration-biopsy produce tumor recurrence in patients following liver transplantation for hepatocellular carcinoma? | Transplant Proc | 2005 | https://conductscience.org/library/papers/16386569 | PubMed |
| 4 | 17539001 | Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. | Liver Transpl | 2007 | https://conductscience.org/library/papers/17539001 | PubMed |
| 5 | 18497692 | Use of the piggyback hepatectomy technique in liver transplant recipients with hepatocellular carcinoma. | Transplantation | 2008 | https://conductscience.org/library/papers/18497692 | PubMed |
| 6 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 7 | 19058754 | Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. | Lancet Oncol | 2009 | https://conductscience.org/library/papers/19058754 | PubMed |
| 8 | 19561458 | Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. | Ann Surg | 2009 | https://conductscience.org/library/papers/19561458 | PubMed |
| 9 | 20070666 | Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. | Am J Transplant | 2010 | https://conductscience.org/library/papers/20070666 | PubMed |
| 10 | 21143097 | Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. | Exp Clin Transplant | 2010 | https://conductscience.org/library/papers/21143097 | PubMed |
| 11 | 21334400 | The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. | J Hepatol | 2011 | https://conductscience.org/library/papers/21334400 | PubMed |
| 12 | 21502763 | High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence. | Digestion | 2011 | https://conductscience.org/library/papers/21502763 | PubMed |
| 13 | 21584928 | Which matters most: number of tumors, size of the largest tumor, or total tumor volume? | Liver Transpl | 2011 | https://conductscience.org/library/papers/21584928 | PubMed |
| 14 | 21695773 | Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. | Liver Transpl | 2011 | https://conductscience.org/library/papers/21695773 | PubMed |
| 15 | 21850692 | Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. | Liver Transpl | 2012 | https://conductscience.org/library/papers/21850692 | PubMed |
| 16 | 21953139 | Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era. | Dig Dis Sci | 2012 | https://conductscience.org/library/papers/21953139 | PubMed |
| 17 | 22047762 | Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. | Lancet Oncol | 2012 | https://conductscience.org/library/papers/22047762 | PubMed |
| 18 | 22151471 | Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation. | Transpl Int | 2012 | https://conductscience.org/library/papers/22151471 | PubMed |
| 19 | 22339891 | Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study. | World J Surg Oncol | 2012 | https://conductscience.org/library/papers/22339891 | PubMed |
| 20 | 22710887 | Factors predicting survival after post-transplant hepatocellular carcinoma recurrence. | J Hepatobiliary Pancreat Sci | 2013 | https://conductscience.org/library/papers/22710887 | PubMed |
Cited by81
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 111 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42930145 | Machine Perfusion and Oncologic Outcomes After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42930145 | PubMed |
| 42477564 | The role of machine perfusion in preventing recurrence after liver transplant for hepatocellular carcinoma: a systematic review and meta-analysis. | BMC Gastroenterol | 2026 | https://conductscience.org/library/papers/42477564 | PubMed |
| 42131696 | Screening and care of patients with graft cirrhosis following liver transplantation. | Can Liver J | 2026 | https://conductscience.org/library/papers/42131696 | PubMed |
| 42130302 | Outcomes of early-stage hepatocellular carcinoma patients treated by resection or ablation: real-life data from the French Administrative Health Care database. | J Liver Cancer | 2026 | https://conductscience.org/library/papers/42130302 | PubMed |
| 42122246 | Recurrence of Colorectal Cancer After Liver Transplant for Isolated Colorectal Liver Metastases: A Narrative Review. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42122246 | PubMed |
| 42073543 | Anti-Tumor Immunity in Solid-Organ Transplant Recipients. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42073543 | PubMed |
| 41899182 | Pre-Transplant Natural Killer Cell Activity Predicts Survival and Tumor Recurrence After Living Donor Liver Transplantation. | J Clin Med | 2026 | https://conductscience.org/library/papers/41899182 | PubMed |
| 41892169 | Systemic Treatment for Hepatocellular Carcinoma Recurrence After Liver Transplantation. | Curr Oncol | 2026 | https://conductscience.org/library/papers/41892169 | PubMed |
| 41647833 | Stereotactic radiation therapy for post-transplant systemic recurrence of hepatocellular carcinoma: safety, efficacy and a nomogram predicting overall survival. | Front Oncol | 2025 | https://conductscience.org/library/papers/41647833 | PubMed |
| 41063733 | China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition). | Liver Cancer | 2025 | https://conductscience.org/library/papers/41063733 | PubMed |
| 41035640 | HDAC inhibitor MS275 reprograms metabolism to induce differentiation and suppress proliferation in hepatocellular carcinoma. | Front Immunol | 2025 | https://conductscience.org/library/papers/41035640 | PubMed |
| 40810857 | Clinical progression and predictors of renal outcomes following liver transplantation: long-term follow-up results from a Taiwanese center. | Updates Surg | 2026 | https://conductscience.org/library/papers/40810857 | PubMed |
| 40808313 | Review Article: Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors. | Aliment Pharmacol Ther | 2025 | https://conductscience.org/library/papers/40808313 | PubMed |
| 40702163 | Prognostic nomogram for recurrence of hepatocellular carcinoma after liver transplantation for decision making on postoperative adjuvant therapy. | Sci Rep | 2025 | https://conductscience.org/library/papers/40702163 | PubMed |
| 40589998 | Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review. | Immunotargets Ther | 2025 | https://conductscience.org/library/papers/40589998 | PubMed |
| 40557335 | Cytomegalovirus Reactivation Is Associated With Lower Rates of Hepatocellular Carcinoma Recurrence After Liver Transplantation. | Transpl Int | 2025 | https://conductscience.org/library/papers/40557335 | PubMed |
| 40492030 | A β-glucosidase extracted from walnut (Juglans regia L.) green husk induces human hepatoma cell apoptosis via ROS-mediated p53 and NF-κB pathway. | Food Sci Biotechnol | 2025 | https://conductscience.org/library/papers/40492030 | PubMed |
| 40458255 | Long-Term Survival and Recurrence in HCC vs. Non-HCC Liver Transplant Recipients: A Two-Decade Longitudinal Analysis. | J Clin Exp Hepatol | 2025 | https://conductscience.org/library/papers/40458255 | PubMed |
| 40413459 | Accuracy of cross-sectional imaging in predicting tumor viability using the LI-RADS treatment response algorithm after image-guided percutaneous ablation with radiologic-pathologic explant correlation. | Cancer Imaging | 2025 | https://conductscience.org/library/papers/40413459 | PubMed |
| 40104187 | Hepatocellular carcinoma recurrence after liver transplant: An Australian single-centre study. | World J Transplant | 2025 | https://conductscience.org/library/papers/40104187 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ADIPOQ | 9370 | PubTator's text mining | https://conductscience.org/library/genes/9370 | NCBI Gene |
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 | NCBI Gene |
| LEP | 3952 | PubTator's text mining | https://conductscience.org/library/genes/3952 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30967904
GET https://conductscience.org/api/papers/v1/30967904/references?page=2